PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

The association between myocardial infarction and intravitreal bevacizumab injection.

Abstract To evaluate the risk of myocardial infarction (MI) after receiving intravitreal bevacizumab (IVB) injection. We retrospectively reviewed the charts of patients who had received IVB injection in 2016, and grouped them according to whether they received the injection for age-related macular degeneration (AMD), diabetes-related complications, or retinal vein occlusion (RVO). We then investigated the prevalence of MI within 2 months after IVB injection and analyzed the possible association of IVB with MI. During 2016, 724 patients were enrolled and received a total of 1870 IVB injections. Seven patients were diagnosed with MI within 2 months after receiving an IVB injection. Of 274 patients with AMD, 2 were diagnosed with MI; of 311 patients with diabetes-related complications, 3 were diagnosed with MI; and of 139 patients with RVO, 2 were diagnosed with MI (P = 0.785). All MIs occurred between 3 days and 3 weeks after IVB injection (mean = 14.00 ± 6.45 days). The MIs after receiving IVB were associated with previous history of MI or cerebrovascular infarction in multivariate logistic regression analysis (P = 0.005). There was no significant difference in MI prevalence after IVB injection according to the reason for receiving the injection. However, care should be taken when administering IVB injections, especially to patients with risk factors such as history of MI or cerebrovascular infarction.
PMID
Related Publications

Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion.

Comparison of intravitreal bevacizumab with intravitreal triamcinolone acetonide for treatment of cystoid macular edema secondary to retinal vein occlusion: a Meta-analysis.

Association Between Hyperreflective Dots on Spectral-Domain Optical Coherence Tomography in Macular Edema and Response to Treatment.

Bevacizumab for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis.

Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29595656
OWN - NLM
STAT- MEDLINE
DCOM- 20180411
LR  - 20180411
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 13
DP  - 2018 Mar
TI  - The association between myocardial infarction and intravitreal bevacizumab
      injection.
PG  - e0198
LID - 10.1097/MD.0000000000010198 [doi]
AB  - To evaluate the risk of myocardial infarction (MI) after receiving intravitreal
      bevacizumab (IVB) injection. We retrospectively reviewed the charts of patients
      who had received IVB injection in 2016, and grouped them according to whether
      they received the injection for age-related macular degeneration (AMD),
      diabetes-related complications, or retinal vein occlusion (RVO). We then
      investigated the prevalence of MI within 2 months after IVB injection and
      analyzed the possible association of IVB with MI. During 2016, 724 patients were 
      enrolled and received a total of 1870 IVB injections. Seven patients were
      diagnosed with MI within 2 months after receiving an IVB injection. Of 274
      patients with AMD, 2 were diagnosed with MI; of 311 patients with
      diabetes-related complications, 3 were diagnosed with MI; and of 139 patients
      with RVO, 2 were diagnosed with MI (P = 0.785). All MIs occurred between 3 days
      and 3 weeks after IVB injection (mean = 14.00 +/- 6.45 days). The MIs after
      receiving IVB were associated with previous history of MI or cerebrovascular
      infarction in multivariate logistic regression analysis (P = 0.005). There was no
      significant difference in MI prevalence after IVB injection according to the
      reason for receiving the injection. However, care should be taken when
      administering IVB injections, especially to patients with risk factors such as
      history of MI or cerebrovascular infarction.
FAU - Kwon, Jin-Woo
AU  - Kwon JW
AD  - Department of Ophthalmology and Visual Science, St Vincent's, Hospital, College
      of Medicine, Catholic University of Korea, Suwon, Korea.
FAU - Jee, Donghyun
AU  - Jee D
FAU - La, Tae Yoon
AU  - La TY
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Angiogenesis Inhibitors)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - AIM
SB  - IM
MH  - Aged
MH  - Angiogenesis Inhibitors/administration & dosage/adverse effects/*therapeutic use
MH  - Bevacizumab/administration & dosage/adverse effects/*therapeutic use
MH  - Diabetic Retinopathy/*drug therapy/epidemiology
MH  - Female
MH  - Humans
MH  - Intravitreal Injections
MH  - Logistic Models
MH  - Macular Degeneration/*drug therapy/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*epidemiology
MH  - Retinal Vein Occlusion/*drug therapy/epidemiology
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Stroke/epidemiology
EDAT- 2018/03/30 06:00
MHDA- 2018/04/12 06:00
CRDT- 2018/03/30 06:00
PHST- 2018/03/30 06:00 [entrez]
PHST- 2018/03/30 06:00 [pubmed]
PHST- 2018/04/12 06:00 [medline]
AID - 10.1097/MD.0000000000010198 [doi]
AID - 00005792-201803300-00029 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Mar;97(13):e0198. doi: 10.1097/MD.0000000000010198.